Skip to content
About
Leadership
Executive Team
Board of Directors
Facilities
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Migraine
Infectious Disease
Lyme Disease
Mpox (Monkey Pox)
Smallpox
Immunology and Immuno-oncology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
TNX-1300
Infectious Disease
TNX-4800
TNX-801
TNX-4200
Immunology and Immuno-oncology
TNX-1500
TNX-1700
TNX-4700
Rare Disease
TNX-2900
Expanded Access Policy
Medicines
Clinical
Clinical Trials
Adverse Event Reporting
Submit a Grant Proposal
Submit a Research Proposal
Pain Guides
Fibromyalgia Pain Guide
Migraine Pain Guide
News & Events
Press Releases
Investor Presentations
Scientific Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Investor Presentations
Scientific Presentations
Program Specific Presentations
Conference Materials
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
June 2015
Serotonin Receptor Profiles of Bedtime Pharmacotherapies Targeting Posttraumatic Stress Disorder (PTSD)
June 2015
TNX-102 SL for Treatment of Fibromyalgia: Approaches to Pain Measurement
June 2015
TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization
August 2015
The (R)-isomer of isometheptene, decreases trigeminal sensitivity in the Inflammatory Soup and Spontaneous Trigeminal Allodynia rat models
August 2015
The AtEase Study: An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD
August 2015
(R)-isometheptene* (IMH) Binds to the Imidazoline-1 Receptor and (S)-IMH increases Blood Pressure: Potentially Superior Benefit-to-Risk Ratio for (R)-IMH as an Analgesic for Headache
November 2013
Cyclobenzaprine (CBP) and its Major Metabolite Norcyclobenzaprine (nCBP) are Potent Antagonists of the Serotonin Receptor 2A, Histamine H1 and α-Adrenergic Receptors: Mechanistic and Safety Implications…
Posts navigation
Newer posts